Genetic polymorphisms of metabolizing enzymes and transporters correlate with pharmacokinetics (PK) and pharmacodynamics (PD) of amrubici
Not Applicable
- Conditions
- lung cancer
- Registration Number
- JPRN-UMIN000002970
- Lead Sponsor
- ational Cancer Center Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 50
Inclusion Criteria
Not provided
Exclusion Criteria
possitive HIV and HCV, and Hbs Patients whose participation inthe trial is judged to be inappropriate by the attending doctor
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method PK parameter of amrubicin and active metabolite amrubicinol
- Secondary Outcome Measures
Name Time Method PK parameters correlate with Hematological toxicity Genetic polymorphisms correlate with PK/PD